Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

4.0%

3 terminated out of 75 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

5%

4 trials in Phase 3/4

Results Transparency

17%

2 of 12 completed with results

Key Signals

2 with results80% success

Data Visualizations

Phase Distribution

50Total
Not Applicable (18)
Early P 1 (2)
P 1 (9)
P 2 (17)
P 3 (3)
P 4 (1)

Trial Status

Recruiting38
Not Yet Recruiting15
Completed12
Enrolling By Invitation3
Terminated3
Active Not Recruiting2

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT07568444Phase 2CompletedPrimary

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

NCT06661044CompletedPrimary

Understanding the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer

NCT07541911Not ApplicableNot Yet Recruiting

A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy

NCT07552922Not ApplicableRecruitingPrimary

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

NCT07439913Enrolling By InvitationPrimary

Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatectomy for Prostate Cancer

NCT06844383Phase 2RecruitingPrimary

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

NCT07484971Recruiting

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

NCT06592924Phase 3RecruitingPrimary

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06801236Phase 1RecruitingPrimary

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07516886Recruiting

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

NCT06834204Not ApplicableNot Yet Recruiting

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT07426055Phase 2RecruitingPrimary

PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer

NCT07332000Phase 2Recruiting

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07460726Not Yet RecruitingPrimary

PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer

NCT07182279Phase 1RecruitingPrimary

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT07444983Not ApplicableNot Yet RecruitingPrimary

Rezvilutamide for High-Risk Prostate Cancer After Surgery

NCT06616597Phase 2RecruitingPrimary

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT07417475Not ApplicableCompletedPrimary

Robot-Assisted Radical Prostatectomy: the HOOD Technique Versus Standard Anterior Reconstruction

NCT07413120Phase 3CompletedPrimary

Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery

Scroll to load more

Research Network

Activity Timeline